Centiva Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-42
| Closed | -$11.6K | – | 1268 |
|
|
2024
Q3 | $11.6K | Sell |
42
-958
| -96% | -$263K | ﹤0.01% | 1485 |
|
|
2024
Q2 | $243K | Buy |
+1,000
| New | +$243K | ﹤0.01% | 1142 |
|
|
2023
Q4 | – | Sell |
-421
| Closed | -$74.6K | – | 1240 |
|
|
2023
Q3 | $74.6K | Buy |
+421
| New | +$74.6K | ﹤0.01% | 1082 |
|
|
2022
Q4 | – | Sell |
-456
| Closed | -$91K | – | 921 |
|
|
2022
Q3 | $91K | Buy |
+456
| New | +$91K | ﹤0.01% | 823 |
|
|
2022
Q2 | – | Sell |
-2,594
| Closed | -$424K | – | 1206 |
|
|
2022
Q1 | $424K | Buy |
+2,594
| New | +$424K | 0.01% | 654 |
|
|
2021
Q4 | – | Sell |
-1,731
| Closed | -$327K | – | 732 |
|
|
2021
Q3 | $327K | Sell |
1,731
-2,945
| -63% | -$556K | 0.02% | 604 |
|
|
2021
Q2 | $793K | Buy |
+4,676
| New | +$793K | 0.02% | 392 |
|
|
2021
Q1 | – | Sell |
-3,296
| Closed | -$428K | – | 911 |
|
|
2020
Q4 | $428K | Buy |
3,296
+94
| +3% | +$12.2K | 0.02% | 352 |
|
|
2020
Q3 | $466K | Buy |
3,202
+499
| +18% | +$72.6K | 0.03% | 257 |
|
|
2020
Q2 | $400K | Buy |
2,703
+2,141
| +381% | +$317K | 0.02% | 213 |
|
|
2020
Q1 | $61K | Buy |
562
+306
| +120% | +$33.2K | ﹤0.01% | 319 |
|
|
2019
Q4 | $29K | Sell |
256
-1,169
| -82% | -$132K | ﹤0.01% | 457 |
|
|
2019
Q3 | $115K | Buy |
+1,425
| New | +$115K | 0.01% | 284 |
|